ATE386523T1 - Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes - Google Patents

Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes

Info

Publication number
ATE386523T1
ATE386523T1 AT02751454T AT02751454T ATE386523T1 AT E386523 T1 ATE386523 T1 AT E386523T1 AT 02751454 T AT02751454 T AT 02751454T AT 02751454 T AT02751454 T AT 02751454T AT E386523 T1 ATE386523 T1 AT E386523T1
Authority
AT
Austria
Prior art keywords
treatment
diabetes
prophylaxis
pharmaceutical compositions
synergistic pharmaceutical
Prior art date
Application number
AT02751454T
Other languages
English (en)
Inventor
Zoltan Szilvassy
Gyoergy Rabloczky
Nagy Peter Literati
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Application granted granted Critical
Publication of ATE386523T1 publication Critical patent/ATE386523T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
AT02751454T 2001-07-17 2002-07-10 Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes ATE386523T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére

Publications (1)

Publication Number Publication Date
ATE386523T1 true ATE386523T1 (de) 2008-03-15

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751454T ATE386523T1 (de) 2001-07-17 2002-07-10 Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes

Country Status (21)

Country Link
US (2) US7635674B2 (de)
EP (1) EP1408966B1 (de)
JP (1) JP4598390B2 (de)
KR (1) KR100920560B1 (de)
CN (1) CN1270713C (de)
AT (1) ATE386523T1 (de)
AU (1) AU2002354884B2 (de)
BR (1) BR0210744A (de)
CA (2) CA2452558C (de)
CY (1) CY1107939T1 (de)
DE (1) DE60225143T2 (de)
DK (1) DK1408966T3 (de)
ES (1) ES2300460T3 (de)
IL (2) IL159412A0 (de)
MX (1) MXPA04000324A (de)
NO (1) NO20040153L (de)
NZ (1) NZ531155A (de)
PL (1) PL205826B1 (de)
PT (1) PT1408966E (de)
RU (1) RU2311907C2 (de)
WO (1) WO2003007951A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582464A1 (en) * 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of ptp1b expression
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
ES2355680T3 (es) * 2006-11-02 2011-03-30 N-Gene Research Laboratories Inc. Reducción del sobrepeso o de la obesidad.
ES2357983T3 (es) * 2006-11-02 2011-05-04 N-Gene Research Laboratories Inc. Composición farmacéutica que presenta una actividad antipsicótica, antidepresiva o antiepiléptica con un efecto secundario reducido.
US7753949B2 (en) * 2007-02-23 2010-07-13 The Trustees Of The University Of Pennsylvania Valve prosthesis systems and methods
EP2185138B1 (de) 2007-07-19 2016-09-07 Takeda Pharmaceutical Company Limited Feste zubereitung mit alogliptin und metforminhydrochlorid
CA2707484C (en) 2007-12-04 2021-08-10 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
AU2012242642A1 (en) 2011-04-13 2013-05-02 Ionis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
KR20240033119A (ko) 2017-06-30 2024-03-12 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
US20210369689A1 (en) * 2020-05-27 2021-12-02 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c9 substrates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Also Published As

Publication number Publication date
NO20040153L (no) 2004-03-16
MXPA04000324A (es) 2004-07-23
RU2004105149A (ru) 2005-04-20
CN1531433A (zh) 2004-09-22
US20100048627A1 (en) 2010-02-25
PT1408966E (pt) 2008-05-02
DE60225143T2 (de) 2009-02-12
IL159412A0 (en) 2004-06-01
JP2004537550A (ja) 2004-12-16
PL205826B1 (pl) 2010-05-31
NZ531155A (en) 2005-07-29
DE60225143D1 (de) 2008-04-03
US7635674B2 (en) 2009-12-22
AU2002354884B2 (en) 2007-10-18
CY1107939T1 (el) 2013-09-04
PL364662A1 (en) 2004-12-13
KR20040029371A (ko) 2004-04-06
ES2300460T3 (es) 2008-06-16
BR0210744A (pt) 2004-07-20
CA2452558A1 (en) 2003-01-30
CA2452558C (en) 2009-12-22
DK1408966T3 (da) 2008-06-16
KR100920560B1 (ko) 2009-10-08
IL159412A (en) 2009-09-22
RU2311907C2 (ru) 2007-12-10
AU2002354884A2 (en) 2003-03-03
EP1408966B1 (de) 2008-02-20
CA2682251A1 (en) 2003-01-30
CN1270713C (zh) 2006-08-23
US8048873B2 (en) 2011-11-01
WO2003007951A1 (en) 2003-01-30
EP1408966A1 (de) 2004-04-21
JP4598390B2 (ja) 2010-12-15
US20070015687A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
DE60225143D1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
ES2191048T3 (es) Derivados de oxazolidinona y compuestos farmaceuticos que los contienen.
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA04006553A (es) Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
NO20006221L (no) Fremgangsmåte for bekjempelse av skadedyr
MXPA04012965A (es) Inhibidores virales.
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
HUP0103781A2 (hu) Megismerési képesség javítására szolgáló gyógyszerkészítmények, melyek atipikus antipszihotikus szer és acetilkolinészteráz inhibitor kombinációját tartalmazzák
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ATE245447T1 (de) Inhibitor von gehirnödemen
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
EA199901012A1 (ru) Фармацевтические композиции на основе тизоксанида и нитазоксанида
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
DE60121459D1 (de) Cyanidinmischung zur behandlung von dickdarmkrebs
RS20050776A (en) A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment diabetes
TW200640464A (en) Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient
UA81608C2 (ru) Синергическая фармацевтическая комбинация для профилактики или лечения диабета
AU2003227008A1 (en) 2-methylthiazolidine-2,4-dicarboxylic acid and the salts thereof used for the treatment of neurodegenerative diseases
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1
ECSP972190A (es) Piridinas sustituidas como inhibidores selectivos de ciclooxigenasa 2

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1408966

Country of ref document: EP